TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00061893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. \[Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.\] .
Study: NCT03648229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol ophthalmic solution
Description: Timolol ophthalmic solution 0.5% for reduction of intraocular pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol ophthalmic solution
Description: Timolol ophthalmic solution 0.5% for reduction of intraocular pressure
Study: NCT01176513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-148 (18F)
Description: All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.
Study: NCT04107324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ARAPS
Description: In a previous experimental study on rats, the investigators have shown that PVE combined with radiofrequency ablation (RFA), hereafter called Associated Radiofrequency Ablation and Portal Vein Ligation for Staged Hepatectomy (ARAPS), can induce accelerated growth of the FLR

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PVE
Description: Portal vein embolisation
Study: NCT04119362

Intervention type: OTHER
Intervention: Quality of live questionnaires
Description: EORTC-Q30 questionnaire, additonal questionnaire on worries about quality of life impairments and on physical condition every 8 weeks. No additional visits will be carried out for questionnaires. Questionnaires will be handed out to patients during routine visits.
Study: NCT04119180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 50 MG/ML
Description: Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hcl 2Mg/Ml Syrup
Description: Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine;

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protective stabilization
Description: The legal guardian or accompanying person appointed by the legal guardian should sit in the dental chair with the child and contain leg and arm movements. A dental assistant keeps the child's head contained during care.
Study: NCT02753426

Intervention type: DRUG
Group type: OTHER
Intervention: Doxycycline
Description: Doxycycline 20mg capsule by mouth, twice a day for 30 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Doxycycline
Description: Doxycycline 20mg capsule by mouth, twice a day for 30 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (for Doxycycline)
Description: Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (for Doxycycline)
Description: Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.
Study: NCT02115295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT02914405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains consisting of 440 amino acids and 2 identical light chains. Molecular weight is 146,221 daltons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ch14.18/CHO
Description: APN311 (ch14.18/CHO) is manufactured in a Good Manufacturing Practice (GMP) compliant facility of Polymun Scientific, Austria according to a state of the art aseptic manufacturing process based on a characterized and stable Chinese Hamster Ovary (CHO) cell line. After propagation of the working cell bank (WCB) in small volume vessels/bioreactors, manufacture is carried out in a 2500 L stirred tank reactor utilizing components which are free of material of animal or human origin.
Study: NCT03171337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture at acupoints for CTTH according to TCM theory using stainless filiform needle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fu's Subcutaneous Needling (FSN)
Description: Fu's subcutaneous needling at specific points for CTTH using soft casing needle.
Study: NCT04119362

Intervention type: OTHER
Intervention: Optional translational project
Description: Collection of archival tumor material for future translational projects. No biopsy will be performed in the context of this registry. Only tumor samples obtained in the context of standard of care and after explicit informed context will be used.
Study: NCT02040805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: Group therapy over approximately 20 weeks, based on a structured manual adapted from the individual CBT workbook for hoarding by Steketee and Frost (2006). Each session will be 2 hours in length and consists of weekly check-ins, psychoeducation about hoarding, developing understanding and awareness of one's hoarding symptoms and patterns, behavior modification, cognitive restructuring, goal-setting, motivational enhancement, in vivo and imaginal exposure for discarding and acquisition, executive skills training (organization, sorting, planning, decision-making, problem-solving, etc.), guidelines on establishing clutter buddies, and relapse prevention. Groups will be led by clinical postdoctoral psychology fellows in the Department of Psychiatry at UCSF.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Facilitated Support Group
Description: Fifteen sessions of peer facilitated, group support, over the course of 20 weeks, based on a structured manualized approach (Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding). Each session will be 2 hours in length. In this model, two trained peers, usually, but not necessarily, with personal lived experience of hoarding, will guide the group chapter by chapter through the Buried in Treasures manual.
Study: NCT02731716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Payment Model
Description: Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Payment Model
Description: Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Payment Model
Description: Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Comparisons
Description: Providers will receive weekly emails showing comparisons in quality metrics and total cost of care. They will be compared to other providers in their provider organization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Comparisons
Description: Providers will receive weekly emails showing comparisons in quality metrics and total cost of care. They will be compared to other providers in their provider organization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A1c Member/Provider Incentive
Description: Attributed members and their PCPs will receive up to $75 for a reduction of a1c by 0.5% per quarter (2 quarters).
Study: NCT04487782

Intervention type: OTHER
Intervention: Focus Groups
Description: The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.

Intervention type: OTHER
Intervention: Focus Groups
Description: The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.

Intervention type: OTHER
Intervention: Focus Groups
Description: The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.

Intervention type: OTHER
Intervention: Focus Groups
Description: The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.
Study: NCT03846960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: using specially adapted VNscope
Description: surfactant administration via thin catheter using a specially adapted VNscope
Study: NCT03171337

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture at non-acupoints using Steinberger placebo needles
Study: NCT02442349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Once daily tablet 80 mg
Study: NCT03109639

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional EUS FNA needle
Description: Participants randomised to Group A will undergo tissues acquisition using the Conventional EUS FNA needle and then crossed over to receive the experimental Acquire EUS- FNB device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional EUS FNA needle
Description: Participants randomised to Group A will undergo tissues acquisition using the Conventional EUS FNA needle and then crossed over to receive the experimental Acquire EUS- FNB device.
Study: NCT03846960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surfactant administration
Description: surfactant administration via thin catheter using a specially adapted VNscope
Study: NCT01505686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan with a 1,5 T MRI scanner
Study: NCT03945812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony Stimulating Factor
Description: Filgrastim, Amgen, California, USA 300 mg/1.0 mL
Study: NCT01725204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib + PegIFN
Study: NCT03109639

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acquire FNB device
Description: Participants randomised to Group B will undergo tissue acquisition using the experimental Acquire EUS FNB device and then crossed over to receive the conventional EUS FNA needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acquire FNB device
Description: Participants randomised to Group B will undergo tissue acquisition using the experimental Acquire EUS FNB device and then crossed over to receive the conventional EUS FNA needle
Study: NCT00761462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
Study: NCT03602365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentle Jogger (GJ)
Description: Gentle jogger is a passive jogging device which passively moves the feet up and down simulating jogging
Study: NCT03420547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE
Description: Intervention will consist of 3 sessions over 6 weeks. Each session will last 2 hours and be conducted with a clinical psychologist or medical social worker. The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.
Study: NCT00452868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5 milligrams a day for 6 weeks
Study: NCT02949999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Study: NCT00761462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-quinolone antibiotic
Description: Common used dose and route
Study: NCT00790270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine
Description: 5 mg orally every 8 hours as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400 mg every 8 hours as needed
Study: NCT02949999

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Voclosporin
Study: NCT00790270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen plus Cyclobenzaprine
Description: Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
Study: NCT00687739

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: leuprolide acetate
Description: 3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate
Description: 3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: 3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: 3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Transdermal
Description: 0.075 mg patch per day for 5 months
Study: NCT02549612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moniri Otovent
Description: Please see arm description.
Study: NCT03945812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma Arm
Description: Platelet Rich Plasma Arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline 9%
Study: NCT00638820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell or Umbilical Cord Blood Transplantation
Description: Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath, Busulfan, Clofarabine
Description: * 12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~* 11 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 10 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 9 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 8 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 7 Rest~* 6 Clofarabine 40 mg/m2 intravenously over 2 hours~* 5 Clofarabine 40 mg/m2 intravenously over 2 hours~* 4 Clofarabine 40 mg/m2 intravenously over 2 hours~* 3 Clofarabine 40 mg/m2 intravenously over 2 hours~* 2 Clofarabine 40 mg/m2 intravenously over 2 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation
Description: Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
Study: NCT02848781

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator (ICD)
Description: An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator (ICD)
Description: An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
Study: NCT02132065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
Study: NCT02279082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-02
Description: Active Experimental Drug
Study: NCT05196386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Admission conciliation interview
Description: Previous treatment conciliation at hospital admission

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Admission conciliation interview
Description: Previous treatment conciliation at hospital admission

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge conciliation interview
Description: Allocated treatment during hospital stay

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Discharge conciliation interview
Description: Allocated treatment during hospital stay

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted pharmaceutical interview
Description: Specific information about treatment delivered by pharmacist
Study: NCT04487886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo to match duvelisib will be taken orally twice per day for 14 days.
Study: NCT03892876

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Auditory High Frequency Tetanizing Stimulation
Description: 50 ms tone pips presented at high frequency for 120 seconds

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Auditory High Frequency Tetanizing Stimulation
Description: 50 ms tone pips presented at high frequency for 120 seconds

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: auditory tone pips with interstimulus interval (ISI) 1 sec

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: auditory tone pips with interstimulus interval (ISI) 1 sec
Study: NCT02081352

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DermaPure™
Description: A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Study: NCT00687739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Transdermal
Description: 0.075 mg patch per day for 5 months
Study: NCT04600206

Intervention type: OTHER
Intervention: Self-report questionnaires
Description: In this longitudinal cohort study, patients and caregivers will not receive an intervention. In addition to the outcomes named in the section Outcome Measures patients and caregivers will complete self-report questionnaires for~Existential distress (Demoralization Scale-II, Death and Dying Distress Scale, Depressive Experiences Questionnaire, Revised Loss Orientation and Life Engagement in Advanced Cancer Scale, Sense of Dignity Item, Patient Dignity Inventory, Marwit-Meuser Caregiver Grief Inventory, Caregiver Guilt Questionnaire)~Need for and utilization of psychosocial support~Resources (Sources of Meaning and Meaning in Life Questionnaire, Questionnaire on the Defiant Power of the Human Spirit) and~Control variables (Memorial Symptom Assessment Scale, PHQ-9 and GAD-7)

Intervention type: OTHER
Intervention: Self-report questionnaires
Description: In this longitudinal cohort study, patients and caregivers will not receive an intervention. In addition to the outcomes named in the section Outcome Measures patients and caregivers will complete self-report questionnaires for~Existential distress (Demoralization Scale-II, Death and Dying Distress Scale, Depressive Experiences Questionnaire, Revised Loss Orientation and Life Engagement in Advanced Cancer Scale, Sense of Dignity Item, Patient Dignity Inventory, Marwit-Meuser Caregiver Grief Inventory, Caregiver Guilt Questionnaire)~Need for and utilization of psychosocial support~Resources (Sources of Meaning and Meaning in Life Questionnaire, Questionnaire on the Defiant Power of the Human Spirit) and~Control variables (Memorial Symptom Assessment Scale, PHQ-9 and GAD-7)
Study: NCT01280305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raloxifene
Description: raloxifene 60 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo bid
Study: NCT03358407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2983559
Description: GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
Study: NCT01705795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab (a-IL-5 antibody)
Description: 750mg mepolizumab four times over four months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nacl four times over four months
Study: NCT01854476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pad-gauze with tranexamic acid (Hemostopan™)
Description: The use of pad-gauze containing tranexamic acid (Hemostopan™)